P E Lønning

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. ncbi DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
    Emelyne Dejeux
    Laboratory for Epigenetics, Centre National de Genotypage, CEA Institut de Génomique, Evry, France
    Mol Cancer 9:68. 2010
  2. ncbi Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
    Stian Knappskog
    Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 65, Bergen, 5020, Norway
    Breast Cancer Res 14:R47. 2012
  3. ncbi Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
    Maria D Cao
    Department of Circulation and Medical Imaging, Norwegian University of Science and Technology NTNU, 7489 Trondheim, Norway
    BMC Cancer 12:39. 2012
  4. ncbi Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
    Elisabet Ognedal Berge
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Mol Cancer 9:173. 2010
  5. ncbi Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
    Lars O Baumbusch
    Department of Genetics, Institute for Cancer Research, Rikshospitalet Radiumhospitalet Medical Center, 0310 Oslo, Norway
    Mol Cancer 5:47. 2006
  6. ncbi Alterations of the retinoblastoma gene in metastatic breast cancer
    Elisabet Ognedal Berge
    Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
    Clin Exp Metastasis 28:319-26. 2011
  7. ncbi Multilocus analysis of SNP and metabolic data within a given pathway
    Vessela N Kristensen
    Department of Genetics, Institute of Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    BMC Genomics 7:5. 2006
  8. ncbi Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes
    Aslaug Aamodt Muggerud
    Department of Genetics, Faculty Division, The Norwegian Radium Hospital, University of Oslo, N 0310 Oslo, Norway
    BMC Cancer 6:59. 2006
  9. ncbi Bone safety of aromatase inhibitors versus tamoxifen
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
    Int J Gynecol Cancer 16:518-20. 2006
  10. ncbi Breast cancer prognostication and prediction in the postgenomic era
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Ann Oncol 18:1293-306. 2007

Collaborators

Detail Information

Publications76

  1. ncbi DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
    Emelyne Dejeux
    Laboratory for Epigenetics, Centre National de Genotypage, CEA Institut de Génomique, Evry, France
    Mol Cancer 9:68. 2010
    ..In this study, we aimed to identify DNA methylation based biomarkers to distinguish patients with locally advanced breast cancer who may benefit from neoadjuvant doxorubicin treatment...
  2. ncbi Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
    Stian Knappskog
    Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 65, Bergen, 5020, Norway
    Breast Cancer Res 14:R47. 2012
    ..ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's potential role in resistance to chemotherapy...
  3. ncbi Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
    Maria D Cao
    Department of Circulation and Medical Imaging, Norwegian University of Science and Technology NTNU, 7489 Trondheim, Norway
    BMC Cancer 12:39. 2012
    ..The aim of our study was to examine the tumor metabolic changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response and long-term survival...
  4. ncbi Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
    Elisabet Ognedal Berge
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Mol Cancer 9:173. 2010
    ..This study is part of a project investigating alterations in pivotal genes as predictive factors to chemotherapy sensitivity in breast cancer...
  5. ncbi Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
    Lars O Baumbusch
    Department of Genetics, Institute for Cancer Research, Rikshospitalet Radiumhospitalet Medical Center, 0310 Oslo, Norway
    Mol Cancer 5:47. 2006
    ..The tumor suppressor gene p53 (TP53) controls numerous signaling pathways and is frequently mutated in human cancers. Novel p53 isoforms suggest alternative splicing as a regulatory feature of p53 activity...
  6. ncbi Alterations of the retinoblastoma gene in metastatic breast cancer
    Elisabet Ognedal Berge
    Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
    Clin Exp Metastasis 28:319-26. 2011
    ..While a non-significant association suggesting RB1 alterations to be linked to therapy resistance was observed, our data do not suggest a major role for RB1 alterations explaining acquired drug resistance...
  7. ncbi Multilocus analysis of SNP and metabolic data within a given pathway
    Vessela N Kristensen
    Department of Genetics, Institute of Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    BMC Genomics 7:5. 2006
    ..One of the greatest challenges facing human geneticists is the identification and characterization of susceptibility genes for common multifactorial diseases and their association to different quantitative phenotypic traits...
  8. ncbi Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes
    Aslaug Aamodt Muggerud
    Department of Genetics, Faculty Division, The Norwegian Radium Hospital, University of Oslo, N 0310 Oslo, Norway
    BMC Cancer 6:59. 2006
    ..A new MetriGenix 4D array proposed for diagnostic use was evaluated...
  9. ncbi Bone safety of aromatase inhibitors versus tamoxifen
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
    Int J Gynecol Cancer 16:518-20. 2006
    ..While an increased fracture rate may have detrimental effects, evidence suggests that enhanced bone loss may be preventable through careful bone mineral density (BMD) assessment and treatment with bisphosphonates...
  10. ncbi Breast cancer prognostication and prediction in the postgenomic era
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Ann Oncol 18:1293-306. 2007
    ..On the basis of these findings, we suggest drug resistance may be explored on the basis of upfront biological hypotheses...
  11. ncbi Adjuvant endocrine treatment of early breast cancer
    Per Eystein Lønning
    Section of Oncology, Department of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Hematol Oncol Clin North Am 21:223-38. 2007
    ..The optimal use of estrogen suppression (ovarian ablation with or without aromatase inhibition) and tamoxifen (administered sequentially or in concert with ovarian ablation) in premenopausal women has yet to be defined...
  12. ncbi Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 26, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 117:31-41. 2009
    ..A possible explanation to our finding is increased ligand receptor binding capacity for E(2) in receptor positive tumours but alternative factors influencing intratumour estrogen disposition cannot be excluded...
  13. ncbi Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 17:217-25. 2006
    ..Any difference in cost/utility between the strategies may be of importance to therapy selection...
  14. ncbi Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
    Per E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    J Clin Oncol 23:5126-37. 2005
    ..To evaluate potential detrimental effects of exemestane on bone and lipid metabolism...
  15. ncbi Aromatase inhibitors--socio-economical issues
    Per E Lønning
    Department of Medicine, Section of Oncology, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 95:137-42. 2005
    ..The aim of this paper is to overview these considerations and put them into perspective by simple illustrations taken from current cost estimates...
  16. ncbi [Aromatase inhibitors in the therapy for breast cancer]
    Per Eystein Lønning
    Seksjon for onkologi, Institutt for indremedisin, Det medisinske fakultet, Universitetet i Bergen, Haukeland Universitetssjukehus, 5021 Bergen
    Tidsskr Nor Laegeforen 125:723-8. 2005
    ..FUTURE PERSPECTIVES: The uncertainties relate to which drug should be used, regimen (monotherapy or sequential treatment with tamoxifen), and potential toxic effects related to long-term oestrogen deprivation...
  17. ncbi Exemestane for breast cancer prevention: a feasible strategy?
    Per E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 11:918s-24s. 2005
    ....
  18. ncbi Aromatase inhibitors--socioeconomical issues
    Per E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Department of Oncology, Haukeland Univeristy Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 106:55-61. 2007
    ..For patient groups with a low-risk of relapse but also patients with a limited life expectancy due to high age, cost-utility estimates may exceed the upper limits generally proposed for costs per quality-adjusted life year gained...
  19. ncbi Breast cancer prognostication and prediction: are we making progress?
    P E Lønning
    Institute of Medicine, University of Bergen, Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 18:viii3-7. 2007
    ..This article will focus on recent advances in prognostication and prediction, with emphasis on findings from gene expression profiling studies...
  20. ncbi Exploring breast cancer estrogen disposition: the basis for endocrine manipulation
    Per E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 17:4948-58. 2011
    ..This model indicates that effective suppression of benign and malignant tissue estrogens as a treatment for ER+ breast cancer requires systemic suppression and will not be markedly affected by local enzyme targeting...
  21. ncbi Recent data on intratumor estrogens in breast cancer
    Per E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Steroids 76:786-91. 2011
    ....
  22. ncbi The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 22:503-14. 2011
    ..This article examines the clinical data with aromatase inhibitors, following a brief summary of their pharmacology...
  23. ncbi Molecular basis for therapy resistance
    Per E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Mol Oncol 4:284-300. 2010
    ....
  24. ncbi Evolution of endocrine adjuvant therapy for early breast cancer
    Per Eystein Lønning
    University of Bergen, Haukeland University Hospital, Institute of Medicine, Department of Oncology, Norway
    Expert Opin Investig Drugs 19:S19-30. 2010
    ..Thus, particular attention is paid to the topic of HER-2 expression as a potential cause of endocrine resistance...
  25. ncbi Additive endocrine therapy for advanced breast cancer - back to the future
    Per Eystein Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 48:1092-101. 2009
    ..Whether patients become resistant to other treatment options may still benefit from megestrol acetate, remains to be explored...
  26. ncbi Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Jonas Lies vei 26, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 118:288-93. 2010
    ..Ongoing studies exploring tissue estrogen levels as well as gene expression profiles on therapy may further improve this important therapeutic area...
  27. ncbi Strength and weakness of phase I to IV trials, with an emphasis on translational aspects
    Per Eystein Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Department of Oncology, Bergen, Norway
    Breast Cancer Res 10:S22. 2008
    ..Although translational research in phase III trials aims to identify optimal markers for clinical use, phase II studies may represent an optimal setting to explore tumour biology and the mechanisms of drug resistance in depth...
  28. ncbi Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    Eur J Cancer 45:527-35. 2009
    ..Neither do we know whether some tumours are more sensitive to particular drugs. This paper summarizes clinical findings up to now with respect to lack of cross-resistance and discuss potential mechanisms involved...
  29. ncbi Indications and limitations of third-generation aromatase inhibitors
    Per Eystein Lønning
    Haukeland University Hospital, Department of Oncology, N 5021, Bergen, Norway
    Expert Opin Investig Drugs 17:723-39. 2008
    ..Use of aromatase inhibitors in postmenopausal breast cancer, initially in advanced disease but recently also for adjuvant therapy, represents a major advance...
  30. ncbi Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression
    Per E Lønning
    Institute of Medicine and Haukeland University Hospital, University of Bergen, Bergen, Norway
    J Steroid Biochem Mol Biol 108:196-202. 2008
    ....
  31. ncbi Aromatase inhibitors in breast cancer
    P E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway
    Endocr Relat Cancer 11:179-89. 2004
    ..Interesting findings such as the lack of cross-resistance between steroidal and non-steroidal compounds should be further explored, as this may add additional information to our understanding of breast cancer biology...
  32. ncbi Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance
    Per Eystein Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    Trends Mol Med 10:113-8. 2004
    ..Similarities between carcinogenic injury and cell damage created by chemotherapeutics suggests that somatic inactivation of such genes is crucially important to drug sensitivity...
  33. ncbi Oestrogen suppression--lessons from clinical studies
    Per Eystein Lønning
    Department of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, 5021 Bergen, Norway
    Best Pract Res Clin Endocrinol Metab 18:33-45. 2004
    ....
  34. ncbi Comparison between aromatase inhibitors and sequential use
    Per Eystein Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 86:275-82. 2003
    ....
  35. ncbi Clinical pharmacokinetics of aromatase inhibitors and inactivators
    Per Lønning
    Section of Oncology, Department of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway
    Clin Pharmacokinet 42:619-31. 2003
  36. ncbi Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients
    J Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Endocrinol Metab 83:2687-93. 1998
    ..54 and 1.27 nmol/L during treatment with D-AG and DL-AG, respectively; P < 0.05)...
  37. ncbi Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 18:2234-44. 2000
    ....
  38. ncbi Aromatase inhibitors and their future role in post-menopausal women with early breast cancer
    P E Lønning
    Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen, Norway
    Br J Cancer 78:12-5. 1998
    ..The results of these trials will help to determine whether anastrozole has any benefits over tamoxifen, the current treatment of choice in post-menopausal women with early breast cancer...
  39. ncbi Stepwise estrogen suppression manipulating the estrostat
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway
    J Steroid Biochem Mol Biol 79:127-32. 2001
    ..Future studies are warranted to explore alterations in gene expression and signaling mechanisms in response to different therapies in tumor tissue in vivo...
  40. ncbi Aromatase inhibition for breast cancer treatment
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 35:38-43. 1996
    ....
  41. ncbi The potential for aromatase inhibition in breast cancer prevention
    P E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 7:4423s-4428s; discussion 4411s-4412s. 2001
    ..Results from ongoing studies examining the toxicity of aromatase inhibitors and inactivators in postmenopausal women will set the stage for future trials that explore them as preventive treatment options...
  42. ncbi Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
    M Hauglid Flågeng
    Institute of Medicine, University of Bergen, Bergen, Norway
    Br J Cancer 101:1253-60. 2009
    ..Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity...
  43. ncbi Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer
    L A Akslen
    The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen N 5021, Norway
    Br J Cancer 105:9-12. 2011
    ..Glomeruloid microvascular proliferation (GMP), a novel histology-based angiogenesis marker, has been associated with decreased survival in several human cancers...
  44. ncbi Pharmacokinetics and metabolism of formestane in breast cancer patients
    P E Lønning
    Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 77:39-47. 2001
    ..These exocons are formed by stereoselective 3-keto reduction, accompanied by reduction of the 4,5-enol function. The exocons do not inhibit human placental aromatase activity in vitro...
  45. ncbi Pharmacology and clinical experience with exemestane
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Expert Opin Investig Drugs 9:1897-905. 2000
    ..Sequential therapy with tamoxifen followed by exemestane is also being compared with tamoxifen monotherapy in the adjuvant setting. In addition, the drug may have potential for breast cancer prevention...
  46. ncbi Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
    J Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Br J Cancer 74:1286-91. 1996
    ..Contrary to previous studies on other aromatase inhibitors, this study revealed an internal consistency between the percentage aromatase inhibition and suppression of plasma oestrone sulphate...
  47. ncbi Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
    T Aas
    Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway
    Eur J Cancer 39:438-46. 2003
    ..001 and P = 0.001, respectively). A key reason for this difference with respect to the factors predicting chemotherapy resistance could be due to the adjuvant use of tamoxifen in all patients harbouring ER-positive tumours...
  48. ncbi High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
    P E Lønning
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Breast Cancer Res Treat 67:111-6. 2001
    ..Such treatment represents a valuable alternative to chemotherapy in selected patients...
  49. ncbi Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment
    H Haarstad
    Department of Oncology, Trondheim University Hospital, Norway
    Acta Oncol 37:365-8. 1998
    ..The response to droloxifene recorded in the present study is in accordance with the response rates to tamoxifen as first-line treatment in identical groups of patients...
  50. ncbi Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 118:237-41. 2010
    ..A substantial interindividual variation in the ratios between the individual estrogen fractions suggests additional effects, like alterations in other enzymes to be involved in the intra-tumor estrogen homeostasis...
  51. ncbi Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide
    P E Lønning
    Department of Therapeutic Oncology and Radiophysics, University of Bergen, Norway
    Br J Cancer 60:107-11. 1989
    ..The possibility that such effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast cancer should be considered...
  52. ncbi Is there a growing role for endocrine therapy in the treatment of breast cancer?
    P E Lønning
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Drugs 60:11-21. 2000
    ....
  53. ncbi Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
    J Norum
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 46:153-64. 2007
    ..Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway...
  54. ncbi Exemestane in breast cancer: current status and future directions
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Breast Cancer 1:S28-33. 2000
    ..The findings from these studies will determine the role of exemestane in early breast cancer and lay the foundation for assessing its potential role in breast cancer prevention...
  55. ncbi Aromatase inhibitors as adjuvant treatment of breast cancer
    Jurgen Geisler
    Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Crit Rev Oncol Hematol 57:53-61. 2006
    ..Finally, we need data on cost-utility with respect to the different strategies as well as with respect to patient age and risk profile...
  56. ncbi Impact of aromatase inhibitors on bone health in breast cancer patients
    Jurgen Geisler
    Institute of Medicine, University of Oslo, Faculty Division at Akershus University Hospital, Sykehusveien 27, N 1478 Lørenskog, Norway
    J Steroid Biochem Mol Biol 118:294-9. 2010
    ....
  57. ncbi Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
    Anette Knudsen
    Department of Neurology, Haukeland University Hospital, Bergen, Norway
    Cancer Immunol Immunother 55:1280-4. 2006
    ..Ri antibodies were not associated with PNS in the patients with breast or ovarian cancer. Neurological data were not available for the SCLC patients, but in these, Ri antibodies were not associated with survival...
  58. ncbi Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study
    J Geisler
    Section of Oncology, Department of Medicine, Haukeland University Hospital, University of Bergen, NO-5021, Bergen, Norway
    Eur J Cancer 42:2968-75. 2006
    ..The bone marker values decreased, although a difference at 6 months of follow-up was still recorded, in particular for the markers of bone synthesis...
  59. ncbi Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione
    D C Johannessen
    Department of Oncology, University Hospital of Bergen, Haukeland Sykehus, Norway
    Br J Cancer 68:393-8. 1993
    ....
  60. ncbi RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer
    S Knappskog
    Department of Molecular Biology, University of Bergen, Bergen, Norway
    Ann Oncol 22:2208-15. 2011
    ....
  61. ncbi Clinico-pharmacological aspects of different hormone treatments
    P E Lønning
    Department of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Eur J Cancer 36:S81-2. 2000
    ..Faslodex, the first representative of the so-called 'pure' oestrogen antagonists, has shown beneficial effects in patients resistant to tamoxifen [4]...
  62. ncbi Microarrays in primary breast cancer--lessons from chemotherapy studies
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Endocr Relat Cancer 8:259-63. 2001
    ..This paper outlines our continuing studies exploring prognostic and, we hope, predictive factors in breast cancer therapy...
  63. ncbi Insulin-like growth factors in breast cancer
    S I Helle
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 35:19-22. 1996
    ....
  64. ncbi Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges
    J Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Clin Breast Cancer 1:297-308; discussion 309. 2001
    ..The present publication summarizes the state of the art with respect to endocrine resistance...
  65. ncbi Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
    S Geisler
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Cancer Res 61:2505-12. 2001
    ..Our findings are consistent with the hypothesis that other defects may act in concert with loss of p53 function, causing resistance to doxorubicin in breast cancers...
  66. ncbi The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy
    S I Helle
    Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Clin Endocrinol Metab 86:227-33. 2001
    ..Our results reveal several alterations in the IGF system during HIV infection with decreased IGF-II levels, increased concentration of IGFBP-2, and an increased IGFBP-3 protease activity in advanced disease...
  67. ncbi Treatment of early breast cancer with conservation of the breast. A review
    P E Lønning
    Department of Oncology and Radiophysics, Haukeland Sykehus, Bergen, Norway
    Acta Oncol 30:779-92. 1991
    ..The need for radiotherapy after local excision for small intraductal (ductal carcinoma in situ) cancers is being addressed in ongoing trials...
  68. ncbi Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
    N Anensen
    Hematology Section, Institute of Medicine, University of Bergen, Bergen, Norway
    Oncogene 31:1533-45. 2012
    ..In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms β and γ expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication...
  69. ncbi The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
    M Chekenya
    Norlux Neuro Oncology Group, Department of Biomedicine, University of Bergen, Bergen, Norway
    Oncogene 27:5182-94. 2008
    ..Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes...
  70. ncbi Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
    S I Helle
    Department of Oncology, Haukeland University Hospital, Bergen, N 5021, Norway
    Br J Cancer 85:147-51. 2001
    ..These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses...
  71. ncbi Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
    S I Helle
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N-5021 Bergen, Norway
    Eur J Cancer 41:694-701. 2005
    ..Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome...
  72. ncbi Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients
    E A Lien
    Department of Pharmacology and Toxicology, University of Bergen, Norway
    Br J Cancer 63:641-5. 1991
    ....
  73. ncbi Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome
    T Aas
    Department of Surgery, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 35:5-8. 1996
    ..Recent studies have demonstrated a correlation between p53-mutations and chemotherapy response...
  74. ncbi Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
    S E Monstad
    Department of Neurology, Haukeland University Hospital, Bergen, Norway
    Clin Exp Immunol 144:53-8. 2006
    ..The results show that the prevalence of Yo antibodies is low in ovarian and breast cancer. Yo antibodies may be associated with advanced cancer, but less often with PNS...
  75. ncbi Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study
    S I Helle
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Br J Cancer 78:14-20. 1998
    ....
  76. ncbi Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer
    S I Helle
    Department of Oncology, Haukelland University Hospital, Bergen, Norway
    Br J Cancer 85:74-7. 2001
    ..Our findings reveal alterations in the IGF-system among a substantial number of patients with large primary breast cancers...